Originally published by our sister publication Gastroenterology & Endoscopy News
By Caroline Helwick
CHARLOTTE, N.C.—Dupilumab improves clinical, symptomatic, histologic and endoscopic aspects of eosinophilic esophagitis up to 24 weeks, with benefits sustained to 52 weeks, according to updated analyses of the phase 3 LIBERTY-EoE-TREET study.
In 2022, the FDA approved dupilumab (Dupixent, Sanofi/Regeneron) for the treatment of EoE in adults and adolescents aged 12 years and older and